TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by AtonRa Partners

AtonRa Partners cut its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 8.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,193 shares of the company’s stock after selling 1,094 shares during the period. TransMedics Group comprises about 1.8% of AtonRa Partners’ investment portfolio, making the stock its 5th biggest holding. AtonRa Partners’ holdings in TransMedics Group were worth $883,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TMDX. Vanguard Group Inc. lifted its position in shares of TransMedics Group by 1.7% during the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after purchasing an additional 29,798 shares during the last quarter. Moody Aldrich Partners LLC lifted its position in shares of TransMedics Group by 110.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after purchasing an additional 24,290 shares during the last quarter. American Century Companies Inc. lifted its position in shares of TransMedics Group by 271.2% during the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after purchasing an additional 355,755 shares during the last quarter. Eagle Health Investments LP lifted its position in shares of TransMedics Group by 78.5% during the third quarter. Eagle Health Investments LP now owns 414,205 shares of the company’s stock worth $22,678,000 after purchasing an additional 182,173 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of TransMedics Group by 31.2% during the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock worth $4,624,000 after purchasing an additional 20,081 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX traded up $5.17 during mid-day trading on Monday, reaching $97.25. 1,259,048 shares of the company’s stock traded hands, compared to its average volume of 691,487. The business’s 50-day moving average price is $82.98 and its 200-day moving average price is $74.89. The stock has a market capitalization of $3.18 billion, a P/E ratio of -126.30 and a beta of 1.99. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $99.63.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The company had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The business’s revenue for the quarter was up 158.6% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Analysts Set New Price Targets

TMDX has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer raised their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Morgan Stanley raised their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Finally, Piper Sandler initiated coverage on shares of TransMedics Group in a report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 736 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now owns 14,375 shares in the company, valued at $1,295,043.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Tamer I. Khayal sold 736 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total transaction of $66,306.24. Following the transaction, the insider now owns 14,375 shares in the company, valued at $1,295,043.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 4,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The disclosure for this sale can be found here. Insiders have sold 117,078 shares of company stock worth $9,972,971 over the last quarter. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.